Epigenomics AG

ECX · F · Healthcare / Diagnostics & Research

0.87EUR+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.87

Open0.87

Day Range0.87 – 0.87

52-Week Range0.84 – 1.56

Volume0

Market Cap812.83K

P/E (TTM)0.00

Forward P/E10.49

EPS-0.27

Dividend Yield0.00%

Beta0.87

50-Day Avg0.9261

200-Day Avg0.9316

About

Epigenomics AG does not have significant operations. Previously, the company was involved in liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Heidelberg, Germany.

Company Details

SectorHealthcare
IndustryDiagnostics & Research
CEODr. Noel Thomas Doheny
Employees1
HeadquartersZiegelhAeuser Landstrasse 3, Heidelberg, Germany, 69120, Germany
Websitehttps://www.epigenomics.com

Leadership

Mr. Hansjorg PlaggemarsMember of Executive Board · b. 1971
Mr. Andreas DannerExecutive Board Member
Frederic HilkeInvestor Relations Officer
Dr. Noel Thomas DohenyChief Executive Officer of Epigenomics Inc.

Financials

Income Statement

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	1.59M	1.51M	2.08M	4.20M	1.86M	1.53M	1.13M	842.00K	6.20M	898.00K	339.00K	0	24.00K
Growth (%)	-	-5.10%	+38.16%	+101.78%	-55.63%	-17.76%	-26.61%	-25.16%	+636.70%	-85.52%	-62.25%	-100.00%	-
Cost of Revenue	487.00K	731.00K	1.18M	1.63M	263.00K	480.00K	268.00K	363.00K	136.00K	474.00K	57.00K	0	-
Gross Profit	1.10M	776.00K	907.00K	2.57M	1.60M	1.05M	857.00K	479.00K	6.07M	424.00K	282.00K	0	-
Gross Margin	69.33%	51.49%	43.56%	61.10%	85.89%	68.69%	76.18%	56.89%	97.81%	47.22%	83.19%	-	-
Operating Expense	8.36M	9.15M	10.19M	15.01M	11.46M	14.35M	15.96M	10.59M	10.23M	16.27M	5.25M	3.41M	-
Operating Income	-7.26M	-8.37M	-9.28M	-12.44M	-9.86M	-13.29M	-15.10M	-10.11M	-4.16M	-15.85M	-4.96M	-3.41M	-333.00K
Operating Margin	-456.99%	-555.67%	-445.63%	-296.07%	-528.70%	-867.06%	-1342.40%	-1201.19%	-67.10%	-1765.03%	-1464.31%	-	-1387.50%
EBITDA	-	-	-	-	-9.93M	-12.57M	-13.99M	-11.07M	-1.94M	-10.20M	-3.38M	-1.06M	-314.00K
EBITDA Margin	-	-	-	-	-532.78%	-820.09%	-1243.56%	-1315.08%	-31.26%	-1136.30%	-997.05%	-	-1308.33%
Net Income	-7.41M	-8.85M	-8.98M	-11.16M	-10.23M	-12.69M	-17.02M	-11.69M	-2.43M	-17.30M	-4.46M	-3.35M	-314.00K
Net Income Margin	-466.69%	-587.52%	-431.56%	-265.67%	-549.09%	-827.92%	-1512.89%	-1387.89%	-39.14%	-1926.95%	-1316.81%	-	-1308.33%
R&D	4.38M	4.69M	5.76M	5.12M	4.33M	6.42M	7.34M	3.66M	3.11M	6.19M	-	-	-
R&D as % of Total Revenue	275.50%	311.08%	276.75%	121.85%	232.24%	418.66%	652.44%	434.56%	50.15%	689.42%	-	-	-
Interest Expense	0	0	0	0	0	550.00K	63.00K	55.00K	52.00K	84.00K	0.2	0	0
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	35.88%	5.60%	6.53%	0.84%	9.35%	0.00%	-	0.00%

Balance Sheet

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	11.08M	11.32M	12.60M	18.22M	19.77M	21.83M	13.99M	6.80M	24.66M	15.85M	12.85M	11.85M	11.62M
Total Liabilities	4.62M	5.21M	5.50M	3.80M	9.20M	3.21M	4.36M	2.93M	2.54M	5.68M	12.85M	11.85M	11.61M
Total Equity	6.46M	6.11M	7.10M	14.42M	10.58M	18.61M	9.63M	3.86M	22.12M	10.17M	0	0	2.00K
Cash	7.21M	6.71M	7.78M	11.53M	12.83M	16.46M	10.15M	3.48M	22.96M	10.04M	2.10M	927.00K	414.00K
Net Debt	-	-	-	-	-	-	-	-	-	4.85M	9.79M	10.46M	10.97M

Cash Flow

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-6.50M	-7.24M	-8.13M	-13.28M	-9.58M	-10.35M	-13.51M	-9.57M	-4.15M	-12.02M	-5.71M	-1.20M	-533.00K
Investing Cash Flow	-20.00K	-853.00K	159.00K	-379.00K	-548.00K	724.00K	47.00K	3.00K	961.00K	-	-	-	-
Financing Cash Flow	11.53M	7.60M	9.03M	17.42M	11.50M	13.27M	7.12M	2.98M	21.62M	-	-	-	-
Capital Expenditure	16.00K	868.00K	206.00K	1.27M	183.00K	91.00K	75.00K	10.00K	35.00K	1.36M	3.00K	0	0
Free Cash Flow	-	-	-	-	-10.16M	-10.46M	-13.63M	-9.59M	-4.19M	-13.39M	-5.71M	-1.20M	-533.00K
FCF to OCF	-	-	-	-	106.09%	101.02%	100.90%	100.22%	100.84%	111.35%	100.00%	100.00%	100.00%

Earnings

Report Date	Nov 11, 2014	May 12, 2015	Nov 27, 2015	Mar 16, 2016
EPS Estimate	-20.80	-32.00	-27.20	30.40
EPS Actual	-22.40	-32.00	-22.40	-6.40
Surprise	-7.69%	0.00%	17.65%	-121.05%
Timing	-	Pre-market	After-hours	After-hours

Key Statistics & Ratios

Market Cap812.83K

Enterprise Value11.88M

Trailing P/E0.00

Forward P/E10.49

PEG Ratio0.00

Price / Sales27.09

Price / Book401.95

EPS-0.27

Book Value0.00

Revenue (TTM)30.00K

Gross Profit (TTM)30.00K

EBITDA-370.00K

Profit Margin0.00%

Operating Margin-941.18%

Return on Equity-31400.00%

Return on Assets-1.68%

Shares Outstanding893.22K

Shares Float622.11K

Beta0.87

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Dec 8, 20231:5
Dec 27, 20221:4
Dec 11, 20201:8